MicroRNAs/NNS
in/IN
Autoimmune/JJ
Sjögren/NN
’/CD
s/NNS
Syndrome/NN
./.
====================
MicroRNAs/NNS
(/(
miRNAs/NNS
)/)
,/,
small/JJ
non-coding/JJ
RNAs/NNS
,/,
have/VBP
been/VBN
implicated/VBN
in/IN
various/JJ
diseases/NNS
and/CC
cellular/JJ
functions/NNS
as/IN
microregulators/NNS
of/IN
gene/NN
expression/NN
./.
====================
Although/IN
the/DT
history/JJ
of/IN
miRNA/JJ
investigation/NN
in/IN
autoimmune/JJ
Sjögren/NN
’/CD
s/NNS
syndrome/NN
(/(
SjS/NN
)/)
is/VBZ
fairly/RB
short/JJ
,/,
a/DT
substantial/JJ
amount/NN
of/IN
data/NNS
has/VBZ
already/RB
been/VBN
accumulated/VBN
./.
====================
These/DT
findings/NNS
clearly/RB
indicate/VBP
potential/JJ
clinical/JJ
implications/NNS
of/IN
miRNAs/NNS
,/,
such/JJ
as/IN
autoantigen/NN
expression/NN
and/CC
autoantibody/NN
production/NN
,/,
viral/JJ
miRNAs/NNS
regulating/VBG
the/DT
calcium/NN
signaling/NN
pathway/NN
,/,
and/CC
aberrant/JJ
immune/JJ
cell/NN
regulation/NN
and/CC
cytokine/NN
production/NN
./.
====================
Research/NN
endeavors/NNS
in/IN
the/DT
field/NN
are/VBP
currently/RB
underway/NN
to/TO
select/VB
disease-specific/JJ
diagnostic/JJ
and/CC
prognostic/JJ
biomarkers/NNS
by/IN
utilizing/VBG
different/JJ
types/NNS
of/IN
tissues/NNS
or/CC
biological/JJ
specimens/NNS
of/IN
SjS/NN
patients/NNS
./.
====================
Various/JJ
techniques/NNS
for/IN
miRNA/JJ
analysis/NN
with/IN
different/JJ
stringencies/NNS
have/VBP
been/VBN
applied/VBN
,/,
with/IN
the/DT
most/JJS
recent/JJ
one/CD
being/VBG
next-generation/NN
sequencing/NN
./.
====================
This/DT
review/NN
compiles/NNS
and/CC
highlights/VBZ
differentially-expressed/VBD
miRNAs/NNS
in/IN
various/JJ
samples/NNS
collected/JJ
from/IN
SjS/NN
patients/NNS
and/CC
their/PRP$
potential/JJ
implications/NNS
in/IN
the/DT
pathogenesis/NN
of/IN
SjS/NN
./.
====================
To/TO
facilitate/VB
the/DT
development/NN
of/IN
miRNA-targeted/JJ
personalized/VBN
therapy/NN
in/IN
the/DT
future/JJ
,/,
we/PRP
urge/VBP
more/RBR
follow-up/JJ
studies/NNS
that/IN
confirm/VBP
these/DT
findings/NNS
and/CC
elucidate/VB
the/DT
immunopathological/JJ
roles/NNS
of/IN
differentially-expressed/JJ
miRNAs/NNS
./.
====================
Furthermore/RB
,/,
improved/VBD
diagnostic/JJ
criteria/NNS
for/IN
the/DT
disease/NN
itself/PRP
will/MD
minimize/VB
sampling/JJ
errors/NNS
in/IN
patient/NN
recruitment/NN
,/,
preventing/VBG
the/DT
generation/NN
of/IN
inconsistent/JJ
data/NNS
./.
====================
MicroRNAs/NNS
(/(
miRNAs/NNS
)/)
are/VBP
single-stranded/VBN
,/,
non-coding/JJ
small/JJ
RNAs/NNS
,/,
whose/WP$
sizes/NNS
range/NN
from/IN
18/CD
to/TO
25/CD
nucleotides/NNS
[/(
1/CD
]/)
./.
====================
They/PRP
play/VBP
indispensable/JJ
roles/NNS
in/IN
regulating/VBG
gene/NN
or/CC
protein/NN
expression/NN
by/IN
enhancing/VBG
mRNA/NN
degradation/NN
or/CC
translational/JJ
repression/NN
./.
====================
It/PRP
has/VBZ
been/VBN
estimated/VBN
that/DT
miRNAs/NNS
control/NN
up/IN
to/TO
60/CD
%/NN
of/IN
protein-coding/VBG
genes/NNS
in/IN
the/DT
human/JJ
genome/NN
at/IN
the/DT
translational/JJ
level/NN
[/(
1/CD
]/)
./.
====================
Critical/JJ
regulatory/JJ
roles/NNS
of/IN
miRNAs/NNS
in/IN
complex/NN
cellular/JJ
and/CC
physiological/JJ
pathways/NNS
have/VBP
been/VBN
extensively/RB
studied/VBN
in/IN
various/JJ
scientific/JJ
fields/NNS
./.
====================
Examples/NNS
of/IN
these/DT
roles/NNS
include/VBP
but/CC
are/VBP
not/RB
limited/JJ
to/TO
:/:
differentiation/NN
,/,
proliferation/NN
,/,
migration/NN
,/,
adhesion/NN
,/,
apoptosis/NN
,/,
hematopoiesis/NN
,/,
and/CC
immune/JJ
development/NN
and/CC
functional/JJ
differentiation/NN
[/(
2/CD
]/)
./.
====================
As/IN
they/PRP
are/VBP
involved/VBN
in/IN
a/DT
variety/NN
of/IN
crucial/JJ
regulatory/JJ
functions/NNS
,/,
any/DT
abnormal/JJ
expression/NN
and/CC
functions/NNS
of/IN
miRNAs/NNS
are/VBP
predicted/VBN
to/TO
have/VB
a/DT
profound/JJ
impact/NN
on/IN
target/NN
molecules/NNS
./.
====================
For/IN
this/DT
reason/NN
,/,
miRNA/JJ
dysregulation/NN
has/VBZ
been/VBN
implicated/VBN
in/IN
a/DT
wide/JJ
range/NN
of/IN
human/JJ
diseases/NNS
,/,
such/JJ
as/IN
cancer/NN
,/,
neurodegenerative/JJ
diseases/NNS
,/,
cardiovascular/JJ
diseases/NNS
,/,
and/CC
autoimmune/JJ
conditions/NNS
./.
====================
In/IN
this/DT
review/NN
,/,
miRNAs/NNS
in/IN
autoimmune/JJ
diseases/NNS
will/MD
be/VB
discussed/VBN
with/IN
a/DT
special/JJ
emphasis/NN
on/IN
autoimmune/JJ
Sjögren/NN
’/CD
s/NNS
syndrome/NN
(/(
SjS/NN
)/)
./.
====================
Translating/VBG
the/DT
discovery/NN
of/IN
unique/JJ
expression/NN
patterns/NNS
and/CC
functions/NNS
of/IN
miRNAs/NNS
in/IN
SjS/NN
into/IN
clinical/JJ
practice/NN
is/VBZ
expected/VBN
to/TO
improve/VB
current/JJ
diagnostic/JJ
and/CC
therapeutic/JJ
challenges/NNS
./.
====================
SjS/NN
is/VBZ
a/DT
chronic/JJ
autoimmune/JJ
disease/NN
that/DT
targets/VBZ
the/DT
exocrine/JJ
glands/NNS
of/IN
the/DT
salivary/JJ
and/CC
lacrimal/JJ
glands/NNS
primarily/RB
,/,
resulting/VBG
in/IN
dry/JJ
mouth/NN
and/CC
dry/JJ
eye/NN
,/,
respectively/RB
./.
====================
Similar/JJ
to/TO
many/JJ
other/JJ
autoimmune/JJ
conditions/NNS
,/,
extraglandular/JJ
manifestations/NNS
are/VBP
commonly/RB
seen/VBN
in/IN
patients/NNS
as/IN
well/RB
./.
====================
Therefore/RB
,/,
SjS/NN
patients/NNS
may/MD
suffer/VB
from/IN
peripheral/autonomic/JJ
neuropathy/JJ
,/,
cognitive/JJ
impairment/JJ
,/,
gastroparesis/NN
,/,
pancreatitis/NN
,/,
autoimmune/JJ
hepatitis/NN
,/,
primary/JJ
biliary/JJ
cirrhosis/NN
,/,
interstitial/JJ
lung/NN
disease/NN
,/,
vasculitis/NN
,/,
arthritis/NN
,/,
fibromyalgia/NN
,/,
and/CC
Raynaud/JJ
’/CD
s/NNS
phenomenon/NN
[/(
3–5/CD
]/)
./.
====================
Approximately/RB
,/,
four/CD
million/NN
Americans/NNS
are/VBP
known/VBN
to/TO
be/VB
affected/VBN
by/IN
this/DT
condition/NN
./.
====================
Current/JJ
criteria/NNS
for/IN
diagnosis/NN
mainly/RB
rely/RB
on/IN
the/DT
modified/VBN
European/NN
and/CC
American/NN
diagnostic/JJ
criteria/NNS
proposed/VBN
in/IN
2002/CD
[/(
6/CD
]/)
,/,
the/DT
SICCA/NN
criteria/NNS
proposed/VBN
in/IN
2012/CD
[/(
7/CD
]/)
,/,
and/CC
the/DT
American/NN
College/NN
of/IN
Rheumatology/JJ
(/(
ACR/NN
)/)
/European/JJ
League/NN
Against/RB
Rheumatism/NN
(/(
EULAR/NN
)/)
criteria/NNS
proposed/VBN
in/IN
2016/CD
[/(
8/CD
]/)
./.
====================
In/IN
general/JJ
,/,
these/DT
guidelines/NNS
consider/NN
serology/NN
for/IN
autoantibodies/NNS
,/,
ocular/JJ
surface/NN
integrity/NN
evaluation/NN
,/,
minor/JJ
salivary/JJ
gland/NN
(/(
MSG/NN
)/)
lip/NN
biopsy/NN
,/,
and/or/CC
salivary/JJ
and/CC
tear/JJ
flow/NN
rates/NNS
as/IN
main/JJ
constituents/NNS
of/IN
diagnosis/NN
./.
====================
With/IN
the/DT
growing/VBG
evidence/NN
of/IN
the/DT
important/JJ
biological/JJ
roles/NNS
of/IN
miRNAs/NNS
in/IN
autoimmune/JJ
diseases/NNS
,/,
such/JJ
as/IN
immune/JJ
cell/NN
lineage/NN
determination/NN
,/,
differentiation/NN
,/,
proliferation/NN
,/,
and/CC
immune/JJ
regulation/NN
,/,
the/DT
identification/NN
of/IN
unique/JJ
miRNA/NN
markers/NNS
has/VBZ
provided/VBN
invaluable/JJ
information/NN
in/IN
understanding/VBG
their/PRP$
potential/JJ
roles/NNS
in/IN
autoimmune/JJ
disease/NN
pathogenesis/NN
./.
====================
The/DT
complexity/NN
of/IN
the/DT
biological/JJ
roles/NNS
of/IN
miRNAs/NNS
partly/RB
stems/NNS
from/IN
the/DT
fact/NN
that/IN
a/DT
single/JJ
miRNA/JJ
targets/NNS
multiple/JJ
downstream/JJ
molecules/NNS
and/CC
a/DT
single/JJ
target/NN
gene/NN
may/MD
be/VB
regulated/VBN
by/IN
multiple/JJ
miRNAs/NNS
./.
====================
In/IN
this/DT
section/NN
,/,
recent/JJ
studies/NNS
on/IN
miRNAs/NNS
in/IN
common/JJ
autoimmune/JJ
conditions/NNS
and/CC
their/PRP$
potential/JJ
roles/NNS
are/VBP
briefly/RB
described/VBN
before/IN
extensive/JJ
discussions/NNS
on/IN
differentially/RB
expressed/VBN
miRNAs/NNS
in/IN
SjS/NN
./.
====================
Systemic/JJ
sclerosis/NN
====================
In/IN
a/DT
recent/JJ
miRNA/NN
study/NN
[/(
9/CD
]/)
,/,
serum/NN
samples/NNS
of/IN
systemic/JJ
sclerosis/NN
(/(
SSc/JJ
)/)
patients/NNS
(/(
n/NN
=/JJ
26/CD
)/)
were/VBD
screened/VBN
for/IN
758/CD
miRNAs/NNS
,/,
of/IN
which/WDT
30/CD
miRNAs/NNS
were/VBD
identified/VBN
as/IN
differentially/RB
upregulated/VBN
miRNAs/NNS
./.
====================
Among/IN
these/DT
30/CD
miRNAs/NNS
,/,
miR-483-5p/JJ
showed/VBD
higher/JJR
expression/NN
level/NN
in/IN
an/DT
independent/JJ
SSc/JJ
cohort/NN
,/,
especially/RB
in/IN
early/JJ
stages/NNS
of/IN
SSc/JJ
./.
====================
The/DT
miRNA/JJ
was/VBD
also/RB
up-regulated/VBD
in/IN
localized/JJ
scleroderma/NN
,/,
but/CC
not/RB
in/IN
systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
or/CC
primary/JJ
SjS/NN
(/(
pSjS/NNS
)/)
,/,
indicating/VBG
that/IN
this/DT
miRNA/JJ
possibly/RB
contributes/VBZ
to/TO
the/DT
development/NN
of/IN
skin/NN
fibrosis/NN
./.
====================
Furthermore/RB
,/,
functional/JJ
assays/NNS
involving/VBG
miR-483-5p/JJ
overexpression/NN
in/IN
fibroblasts/NNS
and/CC
endothelial/JJ
cells/NNS
revealed/VBD
altered/JJ
expression/NN
of/IN
fibrosis-related/JJ
genes/NNS
./.
====================
This/DT
provides/VBZ
strong/JJ
evidence/NN
that/IN
the/DT
serum/NN
miRNA/NN
miR-483-5p/JJ
may/MD
function/VB
as/IN
a/DT
potential/JJ
regulator/NN
of/IN
fibrosis/NN
in/IN
SSc/JJ
./.
====================
Systemic/JJ
lupus/NN
erythematosus/NN
====================
Peripheral/JJ
blood/NN
mononuclear/JJ
cell/NN
(/(
PBMC/NN
)/)
miRNA/JJ
profiles/NNS
in/IN
SLE/NN
(/(
n/NN
=/JJ
8/CD
)/)
were/VBD
compared/VBN
with/IN
those/DT
of/IN
pSjS/JJ
(/(
n/NN
=/JJ
8/CD
)/)
and/CC
healthy/JJ
controls/NNS
(/(
HC/NN
)/)
(/(
n/NN
=/JJ
7/CD
)/)
by/IN
the/DT
Illumina/NN
next-generation/NN
sequencing/NN
technology/NN
(/(
NGS/NN
)/)
[/(
10/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
135/CD
miRNAs/NNS
were/VBD
identified/VBN
as/IN
differentially/RB
expressed/VBN
in/IN
SLE/NN
compared/VBN
to/TO
only/RB
26/CD
miRNAs/NNS
in/IN
pSjS/NN
./.
====================
Of/IN
26/CD
miRNAs/NNS
differentially-expressed/VBD
in/IN
pSjS/NN
,/,
25/CD
miRNAs/NNS
were/VBD
also/RB
commonly/RB
overexpressed/VBN
in/IN
SLE/NN
as/IN
well/RB
./.
====================
Downregulation/NN
of/IN
miR-150-5p/JJ
was/VBD
only/RB
detected/VBN
in/IN
pSjS/NN
,/,
which/WDT
appears/VBZ
to/TO
be/VB
associated/VBN
with/IN
differential/JJ
ratios/NNS
of/IN
B/NN
cells/NNS
in/IN
comparison/NN
with/IN
SLE/NN
[/(
11/CD
]/)
./.
====================
Several/JJ
miRNA/JJ
molecules/NNS
were/VBD
overexpressed/VBN
in/IN
SLE/NN
,/,
but/CC
not/RB
changed/VBN
in/IN
pSjS/NN
,/,
which/WDT
include/VBP
miR-148a-3p/NN
,/,
miR-152/NN
,/,
miR-155/NN
,/,
miR-223/NN
,/,
miR-224/NN
,/,
miR-326/NN
,/,
and/CC
miR-342/NN
./.
====================
Interestingly/RB
,/,
expression/NN
levels/NNS
of/IN
miR-223-5p/JJ
,/,
miR-150-5p/JJ
,/,
miR-155-5p/JJ
and/CC
miR-342-3p/JJ
were/VBD
associated/VBN
with/IN
the/DT
B/NN
cell/NN
subsets/NNS
,/,
such/JJ
as/IN
native/JJ
B/NN
cells/NNS
or/CC
switched/VBD
memory/NN
B/NN
cells/NNS
in/IN
the/DT
PBMC/NN
samples/NNS
./.
====================
As/IN
B/NN
cell/NN
hyperactivity/NN
is/VBZ
characteristic/JJ
in/IN
both/DT
pSjS/NNS
and/CC
SLE/NN
,/,
the/DT
miRNA/JJ
expression/NN
signature/NN
may/MD
serve/VB
to/TO
dissect/VB
the/DT
pathological/JJ
B/NN
cell/NN
regulation/NN
between/IN
those/DT
two/CD
conditions/NNS
./.
====================
Rheumatoid/JJ
arthritis/NN
====================
MiRNAs/NNS
in/IN
synovial/JJ
fluids/NNS
and/CC
plasma/NN
in/IN
rheumatoid/JJ
arthritis/NN
(/(
RA/NN
,/,
n/NN
=/JJ
40/CD
)/)
,/,
osteoarthritis/NN
(/(
OA/NN
,/,
n/NN
=/JJ
38/CD
)/)
,/,
and/CC
HC/NN
(/(
n/NN
=/JJ
30/CD
)/)
were/VBD
analyzed/VBN
by/IN
real-time/JJ
quantitative/JJ
reverse/JJ
transcription-PCR/NN
(/(
qRT-PCR/NN
)/)
[/(
12/CD
]/)
./.
====================
Synovial/JJ
fluid/NN
concentrations/NNS
of/IN
miR-16/NN
,/,
miR-132/NN
,/,
miR-146a/NN
,/,
and/CC
miR-223/NN
were/VBD
significantly/RB
lower/JJR
than/IN
their/PRP$
plasma/NN
concentrations/NNS
,/,
and/CC
there/EX
were/VBD
no/DT
correlations/NNS
between/IN
plasma/NN
and/CC
synovial/JJ
fluid/NN
miRNAs/NNS
./.
====================
Interestingly/RB
,/,
synovial/JJ
tissues/NNS
,/,
fibroblast-like/JJ
synoviocytes/NNS
,/,
and/CC
mononuclear/JJ
cells/NNS
secreted/VBN
miRNAs/NNS
in/IN
distinct/JJ
patterns/NNS
./.
====================
Plasma/NN
miR-132/NN
was/VBD
significantly/RB
higher/JJR
in/IN
HC/NN
than/IN
in/IN
RA/NN
or/CC
OA/NN
with/IN
high/JJ
reliability/NN
,/,
while/IN
synovial/JJ
fluid/NN
concentrations/NNS
of/IN
miR-16/NN
,/,
miR-146a/NNP
,/,
miR-155/NN
,/,
and/CC
miR-223/NN
were/VBD
significantly/RB
higher/JJR
in/IN
RA/NN
than/IN
in/IN
OA/NN
./.
====================
Plasma/NN
miRNAs/NNS
or/CC
the/DT
ratio/NN
of/IN
synovial/JJ
fluid/NN
miRNAs/NNS
to/TO
plasma/NN
miRNAs/NNS
,/,
including/VBG
miR-16/NN
and/CC
miR-146a/NN
,/,
significantly/RB
correlated/VBD
with/IN
disease/NN
activity/NN
./.
====================
Therefore/RB
,/,
the/DT
authors/NNS
proposed/VBD
that/IN
synovial/JJ
fluid/NN
and/CC
plasma/NN
miRNAs/NNS
may/MD
serve/VB
as/IN
diagnostic/JJ
biomarkers/NNS
for/IN
RA/NN
and/CC
OA/NN
./.
====================
Early/JJ
rheumatoid/JJ
arthritis/NN
====================
Whole/IN
sera/NNS
in/IN
early/JJ
rheumatoid/JJ
arthritis/NN
(/(
ERA/NN
)/)
patients/NNS
(/(
n/NN
=/JJ
34/CD
)/)
were/VBD
compared/VBN
with/IN
established/JJ
RA/NN
(/(
n/NN
=/JJ
28/CD
)/)
and/CC
HC/NN
(/(
n/NN
=/JJ
16/CD
)/)
in/IN
an/DT
analysis/NN
of/IN
miR-146a/JJ
,/,
miR-155/NN
,/,
miR-223/NN
,/,
miR-16/NN
,/,
miR-203/NN
,/,
miR-132/NN
and/CC
miR-124a/JJ
expression/NN
by/IN
TaqMan/JJ
qRT-PCR/NN
[/(
13/CD
]/)
./.
====================
The/DT
levels/NNS
of/IN
circulating/VBG
miR-146a/NN
,/,
miR-155/NN
and/CC
miR-16/NN
were/VBD
decreased/VBN
in/IN
the/DT
sera/NNS
of/IN
ERA/NN
patients/NNS
in/IN
comparison/NN
with/IN
established/JJ
RA/NN
./.
====================
Levels/NNS
of/IN
circulating/VBG
miR-223/NN
in/IN
treatment/NN
naive/JJ
ERA/NN
patients/NNS
correlated/VBD
with/IN
disease/NN
activity/NN
./.
====================
However/RB
,/,
neither/CC
miR-16/NN
nor/CC
miR-223/NN
could/MD
distinguish/VB
ERA/NN
from/IN
HC/NN
./.
====================
The/DT
authors/NNS
concluded/VBD
that/IN
circulating/VBG
miR-146a/NN
,/,
miR-155/NN
,/,
and/CC
miR-16/NN
in/IN
the/DT
sera/NNS
of/IN
ERA/NN
could/MD
indicate/VB
an/DT
early/JJ
stage/NN
of/IN
the/DT
disease/NN
./.
====================
Connective/JJ
tissue/NN
diseases/NNS
with/IN
interstitial/JJ
lung/NN
disease/NN
====================
A/DT
recent/JJ
study/NN
explored/VBD
the/DT
correlation/NN
between/IN
miR-200c/JJ
and/CC
the/DT
severity/NN
of/IN
interstitial/JJ
lung/NN
disease/NN
(/(
ILD/NN
)/)
in/IN
patients/NNS
(/(
n/NN
=/JJ
218/CD
)/)
with/IN
connective/JJ
tissue/NN
diseases/NNS
(/(
CTDs/NNS
)/)
[/(
14/CD
]/)
./.
====================
PBMCs/NNS
were/VBD
acquired/VBN
from/IN
SSc/JJ
(/(
n/NN
=/JJ
23/CD
)/)
,/,
dermatomyositis/polymyositis/NN
(/(
DM/PM/NN
,/,
n/NN
=/JJ
29/CD
)/)
,/,
pSjS/JJ
(/(
n/NN
=/JJ
30/CD
)/)
,/,
RA/NN
(/(
n/NN
=/JJ
47/CD
)/)
,/,
and/CC
HC/NN
(/(
n/NN
=/JJ
23/CD
)/)
for/IN
qRT-PCR/NN
analyses/NNS
./.
====================
The/DT
results/NNS
indicated/VBD
that/IN
the/DT
miR-200c/JJ
level/NN
in/IN
the/DT
SSc/JJ
group/NN
was/VBD
significantly/RB
higher/JJR
than/IN
in/IN
the/DT
DM/PM/NN
,/,
pSjS/NN
,/,
and/CC
RA/NN
groups/NNS
./.
====================
The/DT
level/NN
of/IN
miR-200c/JJ
in/IN
the/DT
CTDs/NNS
with/IN
ILD/NN
group/NN
was/VBD
significantly/RB
higher/JJR
than/IN
in/IN
the/DT
CTDs/NNS
without/IN
ILD/NN
group/NN
,/,
and/CC
the/DT
level/NN
in/IN
the/DT
severe/JJ
ILD/NN
group/NN
was/VBD
significantly/RB
higher/JJR
than/IN
in/IN
the/DT
mild/JJ
ILD/NN
group/NN
./.
====================
The/DT
authors/NNS
concluded/VBD
that/IN
the/DT
level/NN
of/IN
miR-200c/JJ
was/VBD
positively/RB
correlated/VBD
with/IN
the/DT
severity/NN
of/IN
ILD/NN
,/,
proposing/VBG
miR-200c/JJ
in/IN
PBMCs/NNS
as/IN
a/DT
biomarker/NN
of/IN
the/DT
severity/NN
of/IN
ILD/NN
in/IN
CTDs/NNS
./.
====================
The/DT
history/JJ
of/IN
investigating/VBG
miRNAs/NNS
in/IN
SjS/NN
is/VBZ
relatively/RB
short/JJ
./.
====================
The/DT
first/JJ
journal/JJ
article/NN
examining/VBG
miRNAs/NNS
in/IN
SjS/NN
was/VBD
published/VBN
only/RB
seven/CD
years/NNS
ago/NN
in/IN
2011/CD
[/(
15/CD
,/,
16/CD
]/)
./.
====================
Studies/NNS
of/IN
miRNAs/NNS
in/IN
SjS/NN
have/VBP
utilized/VBN
different/JJ
types/NNS
of/IN
samples/NNS
,/,
such/JJ
as/IN
MSG/NN
collected/JJ
from/IN
lip/NN
biopsies/NNS
,/,
sera/NNS
,/,
PBMC/NN
,/,
or/CC
monocytes/NNS
from/IN
blood/NN
ppub/NN
,/,
and/CC
saliva/NN
or/CC
exosome/JJ
from/IN
saliva/NN
ppub/NN
[/(
15–19/CD
]/)
./.
====================
Utilization/NN
of/IN
mixed/JJ
populations/NNS
of/IN
cells/NNS
or/CC
saliva/NN
that/DT
contains/VBZ
not/RB
only/RB
host-derived/JJ
but/CC
also/RB
microorganism-derived/VBD
miRNAs/NNS
can/MD
cause/VB
difficulty/NN
in/IN
interpretation/NN
of/IN
the/DT
data/NNS
./.
====================
An/DT
interpretation/NN
of/IN
any/DT
published/VBN
data/NNS
on/IN
miRNAs/NNS
will/MD
require/VB
some/DT
attention/NN
to/TO
the/DT
types/NNS
of/IN
specimens/NNS
and/CC
analysis/NN
methods/NNS
utilized/VBN
in/IN
a/DT
particular/JJ
study/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
exact/JJ
implications/NNS
of/IN
miRNAs/NNS
in/IN
disease/NN
onset/NN
and/CC
regulation/NN
still/RB
await/VBP
exploration/NN
./.
====================
Nonetheless/RB
,/,
the/DT
reported/VBN
SjS-associated/JJ
miRNA/NN
studies/NNS
have/VBP
provided/VBN
valuable/JJ
tools/NNS
to/TO
discover/JJ
the/DT
impact/NN
of/IN
miRNAs/NNS
on/IN
SjS/NN
disease/NN
pathogenesis/NN
./.
====================
This/DT
particular/JJ
review/NN
is/VBZ
organized/VBN
according/VBG
to/TO
the/DT
category/NN
of/IN
specimens/NNS
that/IN
have/VBP
been/VBN
utilized/VBN
to/TO
investigate/VB
miRNA/NN
profiles/NNS
in/IN
SjS/NN
./.
====================
The/DT
intention/NN
of/IN
this/DT
approach/NN
was/VBD
not/RB
necessarily/RB
to/TO
emphasize/VB
cell/target/JJ
tissue/NN
specific/JJ
regulation/NN
of/IN
miRNAs/NNS
but/CC
to/TO
arrange/VB
the/DT
contents/NNS
in/IN
a/DT
chronological/JJ
manner/NN
,/,
which/WDT
happened/VBD
to/TO
coincide/VB
with/IN
shifted/JJ
interests/NNS
in/IN
various/JJ
sample/JJ
utilization/NN
./.
====================
Table/JJ
1/CD
[/(
10/CD
,/,
15/CD
,/,
16/CD
,/,
18–25/CD
]/)
summarizes/VBZ
findings/NNS
./.
====================
Minor/NN
salivary/JJ
gland/NN
lip/NN
biopsy/NN
specimens/NNS
====================
Microarray/NN
analyses/NNS
have/VBP
proven/VBN
to/TO
be/VB
valuable/JJ
in/IN
determining/VBG
differentially-expressed/VBD
miRNAs/NNS
in/IN
the/DT
field/NN
./.
====================
One/CD
of/IN
the/DT
first/JJ
studies/NNS
by/IN
Alevizos/NN
et/FW
al/JJ
./.
====================
[/(
15/CD
]/)
utilizing/VBG
miRNA/JJ
microarray/NN
for/IN
miRNAs/NNS
in/IN
SjS/NN
MSG/NN
revealed/VBD
a/DT
correlation/NN
between/IN
relative/JJ
expression/NN
of/IN
selected/VBN
miRNAs/NNS
and/CC
the/DT
MSG/NN
focus/NN
score/RB
(/(
FS/NN
)/)
./.
====================
Among/IN
those/DT
miRNAs/NNS
,/,
miR-768-3p/JJ
showed/VBD
a/DT
positive/JJ
correlation/NN
whereas/IN
miR-574/NN
showed/VBD
a/DT
negative/JJ
correlation/NN
with/IN
FS/NN
,/,
which/WDT
was/VBD
validated/VBN
as/IN
markers/NNS
of/IN
inflammation/NN
by/IN
qRT-PCR/NN
in/IN
an/DT
independent/JJ
cohort/NN
./.
====================
In/IN
addition/NN
,/,
comparing/VBG
miRNAs/NNS
from/IN
patients/NNS
with/IN
preserved/JJ
vs./CC
low/JJ
salivary/JJ
flow/NN
identified/VBN
nine/CD
of/IN
differentially/RB
expressed/VBN
miRNA/NN
,/,
seven/CD
of/IN
which/WDT
were/VBD
up-regulated/VBN
in/IN
the/DT
group/NN
with/IN
decreased/VBN
salivary/JJ
gland/NN
function/NN
./.
====================
This/DT
suggests/VBZ
that/IN
the/DT
predicted/VBN
targets/NNS
of/IN
upregulated/VBN
miRNA/NN
,/,
which/WDT
was/VBD
associated/VBN
with/IN
salivary/JJ
dysfunction/NN
,/,
may/MD
have/VB
a/DT
protective/JJ
effect/NN
on/IN
epithelial/JJ
cells/NNS
./.
====================
Another/DT
comparative/JJ
microarray/NN
analysis/NN
of/IN
miRNA/JJ
expression/NN
in/IN
the/DT
MSGs/NNS
of/IN
SjS/NN
and/CC
HC/NN
revealed/VBD
distinctive/JJ
miRNA/NN
signatures/NNS
in/IN
SjS/NN
patients/NNS
,/,
associated/VBN
with/IN
glandular/JJ
inflammation/NN
and/CC
dysfunction/NN
[/(
16/CD
]/)
./.
====================
MiRNAs/NNS
that/DT
were/VBD
predicted/VBN
to/TO
target/NN
Ro/SSA/NN
and/CC
La/SSB/NN
autoantigens/NNS
were/VBD
upregulated/VBN
in/IN
the/DT
MSG/NN
tissues/NNS
(/(
miR-181a/NNS
)/)
,/,
salivary/JJ
gland/NN
epithelial/JJ
cells/NNS
(/(
SGEC/NNS
)/)
(/(
miR-200b/NN
)/)
and/CC
PBMC/NN
(/(
miR-223/NN
)/)
of/IN
SjS/NN
in/IN
comparison/NN
with/IN
HC/NN
./.
====================
miR-181a/NN
and/CC
miR-16/NN
overexpression/NN
in/IN
MSG/NN
tissues/NNS
of/IN
SjS/NN
patients/NNS
has/VBZ
been/VBN
previously/RB
shown/VBN
to/TO
be/VB
associated/VBN
with/IN
salivary/JJ
dysfunction/NN
[/(
15/CD
]/)
./.
====================
Interestingly/RB
,/,
down-regulated/VBN
expression/NN
of/IN
let-7b/NN
miRNA/NN
was/VBD
observed/VBN
in/IN
SGECs/NNS
of/IN
SjS/NN
patients/NNS
who/WP
were/VBD
positive/JJ
for/IN
Ro/SSA/NN
and/or/CC
La/SSB/NN
compared/VBN
to/TO
seronegative/JJ
patients/NNS
./.
====================
The/DT
authors/NNS
hypothesized/VBD
that/IN
the/DT
increased/VBN
expression/NN
of/IN
miR-181a/NN
,/,
miR-200b/NN
and/CC
miR-223/NN
miRNAs/NNS
in/IN
SjS/NN
may/MD
represent/VB
a/DT
negative/JJ
feedback/NN
loop/NN
for/IN
the/DT
control/NN
of/IN
the/DT
elevated/JJ
Ro/SSA/NN
and/CC
La/SSB/NN
expression/NN
and/or/CC
their/PRP$
inefficiency/NN
to/TO
regulate/VB
target/NN
expression/NN
./.
====================
In/IN
a/DT
subsequent/JJ
study/NN
in/IN
2015/CD
by/IN
the/DT
same/JJ
group/NN
,/,
the/DT
authors/NNS
further/RB
investigated/VBD
29/CD
SjS/NN
patients/NNS
(/(
20/CD
of/IN
29/CD
positive/JJ
for/IN
anti-Ro/SSA/JJ
and/CC
anti-La/SSB/JJ
)/)
and/CC
24/CD
non-SjS/JJ
sicca/JJ
controls/NNS
to/TO
study/VB
possible/JJ
associations/NNS
between/IN
autoantigen/NN
mRNA/NN
expression/NN
and/CC
disease/NN
features/NNS
[/(
20/CD
]/)
./.
====================
The/DT
upregulated/VBN
levels/NNS
of/IN
miR-16/NN
in/IN
MSGs/NNS
,/,
miR-200b-3p/JJ
in/IN
SGECs/NNS
,/,
and/CC
miR-223/NN
and/CC
miR-483-5p/JJ
in/IN
PBMCs/NNS
of/IN
SjS/NN
patients/NNS
compared/VBD
to/TO
non-SjS/JJ
sicca/NN
controls/NNS
were/VBD
identified/VBN
./.
====================
Interestingly/RB
,/,
the/DT
levels/NNS
of/IN
miR-16/NN
in/IN
MSGs/NNS
and/CC
miR-483-5p/JJ
in/IN
PBMC/NN
of/IN
SjS/NN
were/VBD
not/RB
significantly/RB
altered/JJ
in/IN
their/PRP$
previous/JJ
study/NN
[/(
16/CD
]/)
./.
====================
This/DT
may/MD
be/VB
due/JJ
to/TO
the/DT
heterogeneous/JJ
clinical/JJ
features/NNS
of/IN
SjS/NN
,/,
resulting/VBG
in/IN
subtle/JJ
differences/NNS
in/IN
the/DT
subjects/NNS
recruited/VBN
for/IN
those/DT
two/CD
studies/NNS
./.
====================
Nonetheless/RB
,/,
the/DT
MSG/NN
and/CC
PBMC/NN
levels/NNS
of/IN
let-7b/NN
,/,
miR-16/NN
,/,
and/CC
miR-181a/NN
were/VBD
correlated/VBN
positively/RB
with/IN
Ro52/TRIM21-mRNA/NN
./.
====================
Significantly/RB
lower/JJR
miR-200b-5p/JJ
levels/NNS
were/VBD
also/RB
detected/VBN
in/IN
SjS/NN
patients/NNS
with/IN
mucosa-associated/JJ
lymphoid/JJ
tissue/NN
lymphoma/NN
compared/VBN
to/TO
those/DT
SjS/NN
without/IN
lymphoma/NN
./.
====================
The/DT
exact/JJ
roles/NNS
of/IN
dysregulated/VBN
miRNAs/NNS
in/IN
their/PRP$
study/NN
in/IN
promoting/VBG
autoantigen/NN
expression/NN
and/CC
autoantibody/NN
production/NN
would/MD
be/VB
interesting/JJ
to/TO
follow-up/JJ
./.
====================
Recent/JJ
high-throughput/JJ
approaches/NNS
such/JJ
as/IN
NGS/NN
have/VBP
been/VBN
applied/VBN
to/TO
sequence/NN
entire/VBP
genomes/NNS
or/CC
transcriptomes/VBZ
within/IN
days/NNS
./.
====================
This/DT
technology/NN
has/VBZ
yielded/VBD
exciting/VBG
discovery/NN
of/IN
unknown/JJ
genes/NNS
or/CC
small/JJ
miRNAs/NNS
with/IN
a/DT
challenge/NN
of/IN
mining/JJ
large/JJ
amounts/NNS
of/IN
data/NNS
./.
====================
A/DT
study/NN
utilizing/VBG
NGS/NN
revealed/VBD
several/JJ
previously/RB
unidentified/JJ
miRNAs/NNS
in/IN
the/DT
MSG/NN
of/IN
pSjS/NN
patients/NNS
which/WDT
were/VBD
then/RB
validated/VBD
in/IN
other/JJ
cell/NN
lines/NNS
[/(
21/CD
]/)
./.
====================
The/DT
authors/NNS
found/VBD
hsa-miR-4524b-3p/NN
and/CC
hsa-miR-4524b-5p/NN
and/CC
hsa-miR-5100/NN
particularly/RB
interesting/JJ
to/TO
further/RBR
pursue/NN
./.
====================
Although/IN
the/DT
results/NNS
were/VBD
based/VBN
on/IN
a/DT
relatively/RB
small/JJ
number/NN
of/IN
patient/NN
samples/NNS
,/,
potentially/RB
due/JJ
to/TO
cost-intensive/JJ
NGS/NN
,/,
from/IN
whole/JJ
MSG/NN
biopsy/NN
specimens/NNS
,/,
thus/RB
including/VBG
a/DT
mix/JJ
of/IN
cells/NNS
,/,
the/DT
study/NN
showed/VBD
a/DT
promising/JJ
feasibility/NN
of/IN
discovering/VBG
novel/JJ
miRNAs/NNS
by/IN
NGS/NN
./.
====================
A/DT
number/NN
of/IN
important/JJ
contributions/NNS
to/TO
the/DT
field/NN
of/IN
miRNA/JJ
research/NN
have/VBP
been/VBN
made/VBN
by/IN
identifying/VBG
the/DT
functions/NNS
of/IN
differentially-expressed/JJ
miRNAs/NNS
./.
====================
An/DT
innovative/JJ
study/NN
focusing/VBG
on/IN
Epstein/JJ
Barr/JJ
virus/NN
(/(
EBV/NN
)/)
miRNA/JJ
,/,
ebv-miR-BART13-3p/JJ
,/,
indicated/VBD
the/DT
presence/NN
of/IN
the/DT
miRNA/JJ
in/IN
both/DT
B/NN
cells/NNS
and/CC
SGEC/NN
in/IN
pSjS/NN
salivary/JJ
glands/NNS
[/(
22/CD
]/)
./.
====================
As/IN
EBV/NN
typically/RB
infects/VBZ
B/NN
cells/NNS
,/,
the/DT
authors/NNS
further/RB
demonstrated/VBD
that/IN
ebv-miRBART13-3p/VBP
can/MD
be/VB
transferred/VBN
from/IN
B/NN
cells/NNS
to/TO
SGEC/NN
through/IN
exosomes/NNS
and/CC
that/IN
it/PRP
targets/VBZ
stromal/JJ
interacting/VBG
molecule/NN
1/CD
(/(
STIM1/NN
)/)
and/CC
aquaporin/NN
5/CD
(/(
AQP5/NN
)/)
,/,
which/WDT
are/VBP
important/JJ
regulators/NNS
of/IN
salivary/JJ
secretion/NN
via/IN
the/DT
Ca2+-mediated/JJ
signaling/VBG
pathway/NN
./.
====================
The/DT
data/NNS
suggest/VBP
a/DT
mechanism/NN
by/IN
which/WDT
EBV/NN
can/MD
contribute/VB
to/TO
secretory/JJ
dysfunction/NN
in/IN
SjS/NN
./.
====================
This/DT
might/MD
also/RB
explain/VBP
why/WRB
the/DT
degree/NN
of/IN
immune/JJ
cell/NN
infiltration/NN
and/CC
secretory/JJ
dysfunction/NN
are/VBP
not/RB
always/RB
correlated/VBD
in/IN
SjS/NN
./.
====================
Additionally/RB
,/,
the/DT
role/NN
of/IN
EBV/NN
in/IN
SjS/NN
pathogenesis/NN
needs/VBZ
to/TO
be/VB
revisited/VBN
since/IN
it/PRP
has/VBZ
been/VBN
underestimated/VBN
due/JJ
to/TO
inconsistency/VB
in/IN
the/DT
prevalence/NN
,/,
localization/NN
,/,
or/CC
expression/NN
levels/NNS
of/IN
virus/NN
in/IN
patients/NNS
[/(
26–30/CD
]/)
./.
====================
A/DT
recent/JJ
study/NN
by/IN
Martini/NN
et/FW
al/JJ
./.
====================
investigated/VBN
miR-126/NN
and/CC
miR-335-5p/JJ
in/IN
MSG/NN
biopsies/NNS
and/CC
their/PRP$
known/VBN
target/NN
molecule/NN
,/,
cystatin/NN
S/NN
[/(
23/CD
]/)
./.
====================
The/DT
results/NNS
indicated/VBD
that/IN
salivary/JJ
cystatin/NN
S/NN
was/VBD
significantly/RB
decreased/VBD
in/IN
pSjS/NN
(/(
n=40/CD
)/)
vs./CC
HC/NN
(/(
n/NN
=/JJ
20/CD
)/)
,/,
especially/RB
in/IN
those/DT
with/IN
reduced/VBN
secretory/JJ
function/NN
./.
====================
A/DT
positive/JJ
correlation/NN
was/VBD
observed/VBN
between/IN
salivary/JJ
cystatin/NN
S/NN
and/CC
unstimulated/JJ
flow/NN
rate/NN
./.
====================
Salivary/JJ
cystatin/NN
S/NN
was/VBD
also/RB
significantly/RB
reduced/VBD
in/IN
patients/NNS
with/IN
a/DT
submandibular/JJ
gland/NN
ultrasonography/NN
score/RB
≥2/CD
./.
====================
Interestingly/RB
,/,
the/DT
expression/NN
levels/NNS
of/IN
miR-126/NN
and/CC
miR-335-5P/NN
increased/VBD
inversely/RB
with/IN
salivary/JJ
flow/NN
rate/NN
./.
====================
The/DT
authors/NNS
proposed/VBD
cystatin/NN
S/NN
as/IN
a/DT
promising/JJ
biomarker/NN
for/IN
pSjS/NN
as/IN
it/PRP
strongly/RB
correlated/VBD
with/IN
glandular/JJ
dysfunction/NN
./.
====================
The/DT
cystatin/NN
S/NN
transcript/NN
did/VBD
not/RB
change/VB
significantly/RB
,/,
suggesting/VBG
posttranscriptional/JJ
regulation/NN
./.
====================
Peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
====================
We/PRP
have/VBP
shown/VBN
that/IN
both/CC
miR-146a/NNS
and/CC
miR-155/NN
were/VBD
up-regulated/VBN
in/IN
response/NN
to/TO
the/DT
adaptive/JJ
immune/JJ
response/NN
in/IN
PBMC/NN
derived/VBN
from/IN
SjS/NN
when/WRB
testing/VBG
humans/NNS
and/CC
mice/NNS
[/(
19/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
miR-146a/NN
expression/NN
in/IN
SjS/NN
patients/NNS
as/IN
well/RB
as/IN
in/IN
the/DT
SjS-prone/NN
C57BL/6.NOD-Aec1Aec2/NN
mouse/NN
model/NN
was/VBD
investigated/VBN
to/TO
elucidate/VB
its/PRP$
involvement/NN
in/IN
SjS/NN
pathogenesis/NN
./.
====================
Expression/NN
of/IN
miR-146a/JJ
was/VBD
significantly/RB
increased/VBD
in/IN
SjS/NN
patients/NNS
(/(
n/NN
=/JJ
25/CD
)/)
compared/VBN
with/IN
HC/NN
(/(
n/NN
=/JJ
10/CD
)/)
,/,
and/CC
was/VBD
upregulated/VBN
in/IN
the/DT
salivary/JJ
glands/NNS
of/IN
the/DT
SjS-prone/NN
mouse/NN
at/IN
both/CC
8/CD
weeks/NNS
(/(
prior/JJ
to/TO
disease/NN
onset/NN
)/)
and/CC
20/CD
weeks/NNS
(/(
full-blown/JJ
disease/NN
)/)
of/IN
age/NN
,/,
and/CC
in/IN
the/DT
PBMC/NN
at/IN
20/CD
weeks/NNS
of/IN
age/NN
./.
====================
More/RBR
importantly/RB
,/,
functional/JJ
analysis/NN
revealed/VBD
the/DT
roles/NNS
for/IN
miR-146a/JJ
in/IN
increasing/VBG
phagocytic/JJ
activity/NN
and/CC
suppressing/VBG
inflammatory/JJ
cytokine/NN
production/NN
(/(
tumor/NN
necrosis/NN
factor/NN
α/RB
[/(
TNF-α/JJ
]/)
,/,
interleukin/NN
[/(
IL/NN
]/)
-1β/RB
,/,
macrophage/NN
inflammatory/JJ
protein/NN
[/(
MIP/NN
]/)
-1α/RB
,/,
and/CC
IL-6/NN
)/)
,/,
whereas/IN
cell/NN
migration/NN
,/,
nitric/JJ
oxide/NN
production/NN
,/,
and/CC
expression/NN
of/IN
antigen-presenting/costimulatory/JJ
molecules/NNS
were/VBD
not/RB
affected/VBN
in/IN
human/JJ
monocytic/JJ
THP-1/NN
cells/NNS
./.
====================
Our/PRP$
data/NNS
suggest/VBP
that/IN
abnormal/JJ
expression/regulation/NN
of/IN
miRNAs/NNS
in/IN
innate/JJ
immunity/NN
may/MD
contribute/VB
to/TO
,/,
or/CC
be/VB
indicative/JJ
of/IN
,/,
the/DT
initiation/NN
and/CC
early/JJ
stage/NN
of/IN
SjS/NN
[/(
19/CD
]/)
./.
====================
MiR-146a/DT
is/VBZ
known/VBN
to/TO
be/VB
activated/VBN
by/IN
nuclear/JJ
factor/NN
κB/NN
(/(
NF-κB/NN
)/)
,/,
which/WDT
controls/VBZ
Toll-like/JJ
receptor/NN
(/(
TLR/NN
)/)
/IL-1/NN
receptor/NN
signaling/NN
pathway/NN
through/IN
TNF-associated/JJ
factor/NN
6/CD
(/(
TRAF6/NN
)/)
,/,
IL-1/NN
receptor-associated/JJ
kinase/NN
(/(
IRAK1/NN
)/)
,/,
the/DT
signal/NN
transducer/NN
and/CC
activator/NN
of/IN
transcription/NN
1/CD
(/(
STAT1/NN
)/)
,/,
and/CC
IRF5/NN
[/(
31/CD
]/)
./.
====================
It/PRP
is/VBZ
important/JJ
to/TO
mention/NN
that/DT
the/DT
expression/NN
,/,
the/DT
roles/NNS
,/,
and/CC
the/DT
target/NN
gene/NN
regulation/NN
of/IN
miRNA146a/b/NN
need/RB
to/TO
be/VB
interpreted/VBN
in/IN
the/DT
context/NN
of/IN
a/DT
specific/JJ
disease/NN
entity/NN
as/IN
its/PRP$
regulatory/JJ
mechanisms/NNS
appear/VBP
to/TO
be/VB
more/RBR
complex/NN
than/IN
initially/RB
anticipated/JJ
./.
====================
For/IN
instance/NN
,/,
in/IN
the/DT
PBMC/NN
of/IN
RA/NN
patients/NNS
,/,
the/DT
overexpression/NN
of/IN
miR-146a/NN
was/VBD
found/VBN
without/IN
any/DT
change/NN
in/IN
its/PRP$
target/NN
genes/NNS
[/(
31/CD
]/)
./.
====================
However/RB
,/,
in/IN
SLE/NN
,/,
the/DT
expression/NN
of/IN
miR-146a/NN
was/VBD
decreased/VBN
with/IN
increased/VBN
IRAK1/NN
expression/NN
and/CC
unchanged/JJ
TRAF6/NN
[/(
32/CD
]/)
./.
====================
In/IN
a/DT
study/NN
by/IN
Zilahi/NN
et/FW
al/JJ
./.
====================
[/(
33/CD
]/)
,/,
the/DT
authors/NNS
have/VBP
found/VBN
elevated/JJ
miR-146a/b/NN
in/IN
the/DT
PBMC/NN
of/IN
SjS/NN
with/IN
down-regulated/VBN
IRAK1/NN
and/CC
upregulated/VBD
TRAF6/NN
,/,
detected/VBN
by/IN
RT-PCR/NN
./.
====================
Because/IN
of/IN
these/DT
findings/NNS
,/,
Jacob/NN
et/FW
al/JJ
./.
====================
[/(
34/CD
]/)
hypothesized/VBN
that/IN
TRAF6/NN
could/MD
be/VB
specific/JJ
for/IN
SjS/NN
while/IN
IRAK1/NN
could/MD
be/VB
regarded/VBN
as/IN
a/DT
risk/NN
gene/NN
for/IN
SLE/NN
./.
====================
They/PRP
previously/RB
reported/VBD
a/DT
multiple/JJ
defect/NN
(/(
decrease/NN
)/)
in/IN
the/DT
expression/NN
of/IN
various/JJ
protein/NN
kinase/NN
C/NN
isoenzymes/NNS
(/(
included/VBD
PKC/NN
)/)
in/IN
the/DT
monocytes/NNS
and/CC
T/NN
cells/NNS
of/IN
SLE/NN
patients/NNS
,/,
but/CC
not/RB
existing/VBG
in/IN
SjS/NN
[/(
10/CD
]/)
./.
====================
Therefore/RB
,/,
the/DT
authors/NNS
proposed/VBN
that/IN
TRAF6/NN
contributes/VBZ
to/TO
the/DT
activation/NN
of/IN
the/DT
NF-κB/NN
pathway/NN
by/IN
the/DT
involvement/NN
of/IN
PKC/NN
,/,
which/WDT
exists/VBZ
normally/RB
in/IN
the/DT
disease/NN
,/,
and/CC
TRAF6/NN
gene/NN
could/MD
be/VB
a/DT
new/JJ
biomarker/NN
of/IN
SjS/NN
[/(
33/CD
]/)
./.
====================
Another/DT
study/NN
discovered/VBD
changes/NNS
in/IN
miRNA/JJ
expression/NN
profiles/NNS
in/IN
the/DT
PBMC/NN
of/IN
patients/NNS
with/IN
SLE/NN
(/(
n/NN
=/JJ
8/CD
)/)
,/,
pSjS/JJ
(/(
n/NN
=/JJ
8/CD
)/)
,/,
and/CC
HC/NN
(/(
n/NN
=/JJ
7/CD
)/)
by/IN
the/DT
Illumina/NN
NGS/NN
technology/NN
[/(
10/CD
]/)
,/,
which/WDT
was/VBD
mentioned/VBN
earlier/RBR
for/IN
SLE/NN
in/IN
this/DT
review/NN
./.
====================
This/DT
study/NN
by/IN
Chen/NNP
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
is/VBZ
interesting/JJ
in/IN
the/DT
sense/NN
that/DT
miR-146a/NN
was/VBD
overexpressed/VBN
in/IN
SLE/NN
patient/NN
PBMC/NN
,/,
which/WDT
is/VBZ
inconsistent/JJ
with/IN
the/DT
finding/NN
by/IN
Tang/JJ
et/FW
al/JJ
./.
====================
[/(
32/CD
]/)
that/WDT
showed/VBD
downregulated/JJ
miR-146a/NN
in/IN
the/DT
SLE/NN
PBMC/NN
./.
====================
Chen/NNP
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
hypothesized/VBN
that/IN
this/DT
inconsistency/NN
may/MD
be/VB
due/JJ
to/TO
a/DT
difference/NN
in/IN
the/DT
ethnic/JJ
backgrounds/NNS
of/IN
participants/NNS
in/IN
the/DT
two/CD
studies/NNS
;/:
Chen/NNP
et/FW
al./FW
’/CD
s/NNS
study/NN
[/(
10/CD
]/)
involved/VBN
Europeans/NNS
and/CC
Tang/NNP
et/FW
al./FW
’/CD
s/NNS
study/NN
[/(
32/CD
]/)
involved/VBN
Chinese/JJ
./.
====================
The/DT
authors/NNS
also/RB
indicated/VBD
various/JJ
external/JJ
factors/NNS
as/IN
a/DT
potential/JJ
reason/NN
for/IN
the/DT
discrepancy/NN
,/,
such/JJ
as/IN
dietary/JJ
habits/VBZ
,/,
exposure/NN
to/TO
different/JJ
infectious/JJ
agents/NNS
,/,
and/CC
other/JJ
environmental/JJ
elements/NNS
,/,
which/WDT
may/MD
have/VB
influenced/VBN
miRNAs/NNS
expression/NN
level/NN
in/IN
the/DT
PBMC/NN
of/IN
the/DT
patients/NNS
[/(
35/CD
,/,
36/CD
]/)
./.
====================
In/IN
a/DT
recent/JJ
study/NN
by/IN
Peng/NN
et/FW
al/JJ
./.
====================
[/(
24/CD
]/)
,/,
several/JJ
miRNAs/NNS
with/IN
a/DT
viral/JJ
origin/NN
including/VBG
miR-181a/NN
were/VBD
shown/VBN
to/TO
be/VB
upregulated/VBN
in/IN
PBMC/NN
of/IN
patients/NNS
with/IN
SjS/NN
./.
====================
MicroRNA/NN
profiling/VBG
by/IN
microarrays/NNS
in/IN
Chinese/JJ
patients/NNS
with/IN
pSjS/NN
revealed/VBD
elevated/JJ
miRNA/NN
181a/NN
in/IN
the/DT
PBMC/NN
[/(
24/CD
]/)
./.
====================
MiRNA/NN
expression/NN
was/VBD
initially/RB
profiled/VBN
in/IN
female/JJ
patients/NNS
(/(
4/CD
pSjS/NNS
and/CC
3/CD
HC/NN
)/)
,/,
followed/VBN
by/IN
a/DT
large/JJ
cohort/JJ
of/IN
patients/NNS
(/(
n/NN
=/JJ
33/CD
)/)
and/CC
HC/NN
(/(
n/NN
=/JJ
10/CD
)/)
./.
====================
Among/IN
the/DT
202/NN
miRNAs/NNS
that/DT
were/VBD
upregulated/VBN
and/CC
180/CD
miRNAs/NNS
that/DT
were/VBD
downregulated/VBN
in/IN
the/DT
patients/NNS
with/IN
pSjS/JJ
,/,
the/DT
authors/NNS
confirmed/VBD
that/IN
miR-181a/NN
was/VBD
the/DT
most/JJS
profoundly/RB
differentially/RB
expressed/VBN
in/IN
pSjS/JJ
in/IN
comparison/NN
with/IN
HC/NN
./.
====================
The/DT
authors/NNS
speculate/VBP
that/IN
elevated/JJ
miR-181a/NN
levels/NNS
in/IN
the/DT
PBMC/NN
of/IN
these/DT
patients/NNS
compromise/VBP
the/DT
maturation/NN
of/IN
B/NN
cells/NNS
,/,
thus/RB
enabling/VBG
them/PRP
to/TO
recognize/VB
and/CC
attack/NN
autoantigens/NNS
and/CC
resulting/VBG
in/IN
disease/NN
phenotypes/NNS
[/(
24/CD
]/)
./.
====================
Interestingly/RB
,/,
many/JJ
virus-derived/JJ
miRNA/NN
were/VBD
unexpectedly/RB
upregulated/VBD
in/IN
the/DT
SjS/NN
patients/NNS
,/,
suggesting/VBG
that/IN
viral/JJ
infection/NN
of/IN
PBMC/NN
may/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
SjS/NN
./.
====================
Although/IN
the/DT
sources/NNS
and/CC
compositions/NNS
of/IN
the/DT
cells/NNS
were/VBD
different/JJ
,/,
the/DT
detection/NN
of/IN
viral/JJ
miRNAs/NNS
in/IN
PBMC/NN
by/IN
Peng/NN
et/FW
al/JJ
./.
====================
[/(
24/CD
]/)
was/VBD
in/IN
line/NN
with/IN
the/DT
study/NN
investigating/VBG
the/DT
salivary/JJ
glands/NNS
by/IN
Gallo/JJ
et/FW
al/JJ
./.
====================
[/(
22/CD
]/)
./.
====================
The/DT
former/JJ
showing/VBG
the/DT
presence/NN
of/IN
EBV/NN
miRNAs/NNS
and/CC
the/DT
upregulation/NN
of/IN
miRNA-181a/NN
in/IN
B/NN
cells/NNS
,/,
where/WRB
EBV/NN
establishes/NNS
cell/NN
tropism/NN
,/,
provides/VBZ
a/DT
convincing/VBG
scenario/NN
that/DT
viral/JJ
miRNAs/NNS
may/MD
drive/VB
the/DT
expression/NN
of/IN
host/NN
miRNAs/NNS
in/IN
a/DT
cell-specific/JJ
manner/NN
./.
====================
The/DT
latter/JJ
study/NN
,/,
mentioned/JJ
earlier/RBR
,/,
demonstrated/VBD
that/IN
ebv-miR-BART13-3p/VBP
was/VBD
present/JJ
in/IN
both/DT
B/NN
cells/NNS
and/CC
salivary/JJ
epithelial/JJ
cells/NNS
in/IN
pSjS/NN
salivary/JJ
glands/NNS
./.
====================
The/DT
authors/NNS
further/RB
demonstrated/VBD
the/DT
transfer/NN
of/IN
ebv-miR-BART13-3p/JJ
from/IN
B/NN
cells/NNS
to/TO
salivary/JJ
epithelial/JJ
cells/NNS
through/IN
exosomes/NNS
,/,
suggesting/VBG
a/DT
possibility/NN
of/IN
its/PRP$
role/NN
in/IN
compromising/VBG
calcium/NN
signaling/NN
by/IN
targeting/VBG
STIM1/NN
and/CC
consequent/JJ
secretory/JJ
dysfunction/NN
./.
====================
The/DT
establishment/NN
of/IN
the/DT
interplay/NN
between/IN
viral/JJ
miRNA/NN
and/CC
host/NN
miRNA/NN
will/MD
provide/VB
the/DT
exact/JJ
etiological/JJ
and/CC
pathological/JJ
link/NN
between/IN
viral/JJ
infection/NN
and/CC
SjS/NN
./.
====================
Monocytes/NNS
====================
Monocytes/NNS
represent/JJ
a/DT
relatively/RB
homogenous/JJ
population/NN
of/IN
important/JJ
precursor/NN
cells/NNS
to/TO
peripheral/JJ
macrophages/NNS
and/CC
dendritic/JJ
cells/NNS
[/(
18/CD
]/)
./.
====================
Monocytes/NNS
have/VBP
innate/JJ
immune/JJ
functions/NNS
including/VBG
immunomodulation/NN
,/,
cytokine/NN
production/NN
,/,
and/CC
phagocytosis/NN
[/(
37/CD
]/)
./.
====================
In/IN
SjS/NN
,/,
monocytes/NNS
secrete/VBP
pro-inflammatory/JJ
cytokines/NNS
such/JJ
as/IN
IL-6/NN
and/CC
B/NN
cell-activating/JJ
factor/NN
(/(
BAFF/NN
)/)
upon/IN
stimulation/NN
[/(
38/CD
]/)
,/,
express/VBP
type/NN
I/CD
interferon/NN
(/(
IFN/NN
)/)
-regulated/JJ
genes/NNS
[/(
39/CD
,/,
40/CD
]/)
with/IN
reduced/VBN
expression/NN
of/IN
NFκB/JJ
inhibitor/NN
(/(
IκBα/NNP
)/)
[/(
41/CD
]/)
,/,
and/CC
show/VBP
decreased/VBD
phagocytosis/NN
of/IN
apoptotic/JJ
cells/NNS
[/(
42/CD
]/)
./.
====================
Thus/RB
,/,
monocytes/NNS
reflect/VBP
the/DT
inflammatory/JJ
state/NN
in/IN
SjS/NN
patients/NNS
and/CC
mature/JJ
monocytes/NNS
are/VBP
proposed/VBN
to/TO
contribute/VB
to/TO
salivary/JJ
gland/NN
inflammation/NN
in/IN
SjS/NN
[/(
43/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
published/VBN
in/IN
2016/CD
,/,
monocytes/NNS
purified/VBN
from/IN
pSjS/JJ
(/(
n/NN
=/JJ
18/CD
)/)
blood/NN
samples/NNS
were/VBD
compared/VBN
by/IN
miRNA/JJ
microarray/NN
with/IN
those/DT
purified/VBN
from/IN
other/JJ
disease/NN
controls/NNS
of/IN
RA/NN
(/(
n/NN
=/JJ
10/CD
)/)
,/,
SLE/NN
(/(
n/NN
=/JJ
10/CD
)/)
,/,
and/CC
HC/NN
(/(
n/NN
=/JJ
10/CD
)/)
[/(
18/CD
]/)
./.
====================
To/TO
validate/VB
selected/VBN
miRNAs/NNS
from/IN
the/DT
microarray/NN
analysis/NN
,/,
the/DT
microarray/NN
cohort/NN
and/CC
a/DT
new/JJ
cohort/NN
of/IN
monocyte/NN
RNA/NN
samples/NNS
from/IN
9/CD
HC/NN
,/,
12/CD
SjS/NN
,/,
8/CD
SLE/NN
,/,
and/CC
9/CD
RA/NN
patients/NNS
were/VBD
evaluated/VBN
by/IN
qRT-PCR/NN
./.
====================
We/PRP
demonstrated/VBD
that/IN
miR-34b-3p/JJ
,/,
miR-4701-5p/JJ
,/,
miR-609/NN
,/,
miR-300/NN
,/,
miR-3162-3p/JJ
,/,
and/CC
miR-877-3p/JJ
were/VBD
differentially/RB
expressed/VBN
in/IN
43/CD
%/NN
of/IN
pSjS/JJ
patients/NNS
compared/VBD
to/TO
5.8/CD
%/NN
and/CC
5.6/CD
%/NN
for/IN
SLE/NN
and/CC
RA/NN
,/,
respectively/RB
./.
====================
Interestingly/RB
,/,
the/DT
canonical/JJ
transforming/VBG
growth/NN
factor/NN
β/RB
(/(
TGF-β/NN
)/)
signaling/NN
pathway/NN
showed/VBD
the/DT
greatest/JJS
coverage/NN
of/IN
predicted/VBN
targets/NNS
,/,
averaging/VBG
40.5/CD
%/NN
±/CD
23.1/CD
%/NN
pathway/NN
coverage/NN
for/IN
the/DT
six/CD
SjS-associated/JJ
miRNAs/NNS
./.
====================
This/DT
suggests/VBZ
that/IN
these/DT
miRNAs/NNS
preferentially/RB
target/NN
the/DT
canonical/JJ
transforming/VBG
growth/NN
factor/NN
β/NN
(/(
TGFβ/NN
)/)
signaling/NN
pathway/NN
as/IN
opposed/VBN
to/TO
pro-inflammatory/JJ
IL-12/NN
and/CC
Toll-like/JJ
receptor/NFkB/NN
pathways/NNS
in/IN
SjS/NN
pathogenesis/NN
[/(
18/CD
]/)
./.
====================
As/IN
our/PRP$
study/NN
was/VBD
limited/JJ
to/TO
RNA/NN
analyses/NNS
,/,
relationships/VBZ
between/IN
miRNAs/NNS
and/CC
their/PRP$
post-transcriptional/JJ
inhibition/NN
of/IN
target/NN
genes/NNS
at/IN
the/DT
protein/NN
level/NN
need/VBD
to/TO
be/VB
addressed/VBN
as/IN
soon/RB
as/IN
sufficient/JJ
human/JJ
monocytes/NNS
are/VBP
collected/VBN
./.
====================
Nevertheless/RB
,/,
SMAD4/NN
gene/NN
expression/NN
exhibited/VBD
repression/NN
in/IN
a/DT
subpopulation/NN
of/IN
pSjS/NN
patients/NNS
by/IN
our/PRP$
SjS-associated/JJ
miRNAs/NNS
[/(
18/CD
]/)
./.
====================
The/DT
SMAD4/NN
protein/NN
of/IN
the/DT
family/NN
of/IN
TGFβ/NN
signaling/NN
molecules/NNS
acts/VBZ
as/IN
an/DT
essential/JJ
common/JJ
mediator/NN
for/IN
receptor-regulated/JJ
SMADs/NNS
to/TO
enter/VB
the/DT
nucleus/NN
./.
====================
Interestingly/RB
,/,
miR-300/NN
and/CC
miR-609/NN
showed/VBD
the/DT
strongest/JJS
co-association/NN
by/IN
regression/NN
analyses/NNS
and/CC
target/NN
prediction/NN
analyses/NNS
,/,
which/WDT
indicates/VBZ
that/IN
SMAD4/NN
may/MD
be/VB
targeted/VBN
by/IN
SjS-associated/JJ
miRNAs/NNS
in/IN
a/DT
cooperative/JJ
manner/NN
./.
====================
To/TO
our/PRP$
knowledge/NN
,/,
this/DT
is/VBZ
the/DT
only/RB
study/NN
where/WRB
SjS/NN
monocytes/NNS
were/VBD
analyzed/VBN
for/IN
miRNA/JJ
profiling/VBG
./.
====================
T/NN
and/CC
B/NN
lymphocytes/NNS
====================
Dysregulated/JJ
miRNA/NN
expression/NN
in/IN
purified/VBN
T/NN
and/CC
B/NN
lymphocytes/NNS
from/IN
patients/NNS
with/IN
pSjS/NN
was/VBD
reported/VBN
this/DT
year/NN
[/(
25/CD
]/)
./.
====================
The/DT
authors/NNS
purified/VBN
CD4＋/NN
T/NN
cells/NNS
and/CC
CD19＋/NN
B/NN
cells/NNS
from/IN
PBMC/NN
of/IN
two/CD
independent/JJ
cohorts/NNS
./.
====================
Cohorts/NNS
of/IN
pSjS/JJ
and/CC
HC/NN
for/IN
discovery/NN
(/(
n/NN
=/JJ
17/CD
and/CC
n/NN
=/JJ
15/CD
,/,
respectively/RB
)/)
and/CC
another/DT
cohort/NN
for/IN
replication/NN
(/(
27/CD
for/IN
T/NN
cells/NNS
and/CC
25/CD
for/IN
B/NN
cells/NNS
for/IN
pSjS/JJ
and/CC
12/CD
HC/NN
,/,
respectively/RB
)/)
were/VBD
included/VBN
in/IN
the/DT
study/NN
./.
====================
The/DT
Exiqon/JJ
system/NN
containing/VBG
372/CD
miRNAs/NNS
was/VBD
utilized/VBN
./.
====================
In/IN
T/NN
lymphocytes/NNS
,/,
the/DT
study/NN
showed/VBD
upregulation/NN
of/IN
haslet-7d-3p/JJ
,/,
hsa-miR-155-5p/NN
,/,
hsa-miR-222-3p/NN
,/,
hsa-miR-30c-5p/NN
,/,
hsa-miR-146a-5p/NN
,/,
hsa-miR-378a-3p/NN
and/CC
hsa-miR-28–5/NN
p/NN
in/IN
both/DT
the/DT
discovery/NN
and/CC
the/DT
replication/NN
cohorts/NNS
./.
====================
In/IN
B/NN
lymphocytes/NNS
,/,
hsa-miR-378a-3p/NN
,/,
hsa-miR-222-3p/NN
,/,
hsa-miR-26a-5p/NN
,/,
hsa-miR-30b-5p/NN
,/,
and/CC
hsa-miR-19b-3p/NN
were/VBD
significantly/RB
differentially/RB
expressed/VBN
./.
====================
Interestingly/RB
,/,
expression/NN
of/IN
BAFF/NN
mRNA/NN
was/VBD
inversely/RB
correlated/VBN
with/IN
the/DT
down-regulated/VBN
expression/NN
of/IN
hsa-miR-30b-5p/NN
in/IN
B/NN
cells/NNS
from/IN
SjS/NN
patients/NNS
./.
====================
Furthermore/RB
,/,
transfection/NN
of/IN
THP-1/NN
cells/NNS
with/IN
an/DT
antagomir/JJ
(/(
miRNA/JJ
inhibitor/NN
)/)
for/IN
hsa-miR-30b-5p/NN
led/VBD
to/TO
a/DT
strong/JJ
increase/NN
in/IN
BAFF/NN
expression/NN
,/,
providing/VBG
strong/JJ
evidence/NN
that/IN
the/DT
loss/NN
of/IN
hsa-miR30b-5p/NN
could/MD
contribute/VB
to/TO
the/DT
increased/VBN
expression/NN
of/IN
BAFF/NN
in/IN
patients/NNS
with/IN
pSjS/JJ
[/(
25/CD
]/)
./.
====================
Tear/JJ
,/,
saliva/NN
,/,
and/CC
serum/NN
====================
Biomarkers/NNS
====================
A/DT
review/NN
article/NN
on/IN
biomarkers/NNS
in/IN
pSjS/NN
by/IN
Chen/NNP
et/FW
al/JJ
./.
====================
[/(
44/CD
]/)
emphasizes/VBZ
the/DT
importance/NN
of/IN
bodily/RB
fluids/NNS
such/JJ
as/IN
saliva/JJ
,/,
tear/JJ
,/,
and/CC
serum/NN
as/IN
ideal/JJ
sources/NNS
for/IN
biomarker/NN
studies/NNS
./.
====================
According/VBG
to/TO
the/DT
review/NN
,/,
a/DT
number/NN
of/IN
putative/JJ
saliva/NN
biomarkers/NNS
have/VBP
been/VBN
identified/VBN
by/IN
quantitative/JJ
proteomics/NNS
,/,
and/CC
the/DT
combined/JJ
studies/NNS
such/JJ
as/IN
salivary/JJ
proteomics/NNS
and/CC
miRNA/JJ
screening/NN
may/MD
improve/VB
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
biomarkers/NNS
for/IN
disease/NN
./.
====================
The/DT
biomarkers/NNS
identified/VBN
in/IN
bodily/RB
fluids/NNS
for/IN
pSjS/NN
,/,
which/WDT
is/VBZ
summarized/VBN
in/IN
the/DT
review/NN
by/IN
Chen/NNP
et/FW
al/JJ
./.
====================
[/(
44/CD
]/)
,/,
include/VBP
but/CC
are/VBP
not/RB
limited/JJ
to/TO
:/:
profilin/NN
and/CC
anhydrase/CC
I/NN
in/IN
saliva/FW
[/(
45/CD
]/)
,/,
IL-4/NN
and/CC
IL-5/NN
in/IN
saliva/FW
[/(
46/CD
]/)
,/,
Cathepsin/NN
S/NN
in/IN
tear/JJ
[/(
47/CD
]/)
,/,
Myxovirus-resistance/NN
protein/NN
A/DT
(/(
MxA/NNP
)/)
in/IN
whole/JJ
blood/NN
[/(
48/CD
]/)
,/,
Fms-like/JJ
tyrosine/NN
kinase/NN
3/CD
ligand/NN
(/(
Flt-3L/NN
)/)
in/IN
serum/NN
[/(
49/CD
]/)
,/,
and/CC
CXCL13/NN
in/IN
serum/NN
and/CC
saliva/FW
[/(
50/CD
]/)
./.
====================
It/PRP
is/VBZ
well/RB
accepted/VBN
that/IN
IFN/NN
type/NN
I/CD
signature/NN
in/IN
PBMC/NN
and/CC
the/DT
salivary/JJ
glands/NNS
serves/VBZ
as/IN
a/DT
valuable/JJ
pSjS/NN
biomarker/NN
[/(
51/CD
]/)
./.
====================
MxA/NN
level/NN
in/IN
monocytes/NNS
and/CC
in/IN
whole/JJ
blood/NN
has/VBZ
been/VBN
correlated/VBN
with/IN
IFN/NN
score/NN
and/CC
pSjS/NN
disease/NN
activity/NN
[/(
48/CD
]/)
./.
====================
The/DT
level/NN
of/IN
MxA/NN
was/VBD
reportedly/RB
reduced/VBD
after/IN
treatment/NN
with/IN
hydroxychloroquine/NN
,/,
which/WDT
also/RB
supports/VBZ
the/DT
potentially/RB
important/JJ
role/NN
of/IN
MxA/NN
as/IN
a/DT
disease/NN
biomarker/NN
[/(
48/CD
]/)
./.
====================
Utilization/NN
of/IN
the/DT
enzyme/NN
immunoassay/NN
in/IN
the/DT
cited/VBN
study/NN
suggested/VBD
MxA/NN
</JJR
100/CD
μg/L/NN
as/IN
low/JJ
,/,
and/CC
MxA/NN
>/JJR
100/CD
μg/L/NN
as/IN
high/JJ
[/(
48/CD
]/)
./.
====================
Flt-3L/NN
in/IN
serum/NN
might/MD
be/VB
associated/VBN
with/IN
lymphoma/NN
development/NN
in/IN
SjS/NN
[/(
49/CD
]/)
./.
====================
An/DT
interesting/JJ
study/NN
by/IN
Tobon/NN
et/FW
al/JJ
./.
====================
[/(
49/CD
]/)
reported/VBD
that/IN
the/DT
levels/NNS
of/IN
Flt-3L/NN
were/VBD
associated/VBN
with/IN
previously-identified/VBN
risk/NN
factors/NNS
for/IN
lymphoma/NN
development/NN
,/,
such/JJ
as/IN
presence/NN
of/IN
purpura/JJ
,/,
lymphocytopenia/NN
,/,
lower/JJR
levels/NNS
of/IN
C4/NN
and/CC
IgM/NN
,/,
higher/JJR
levels/NNS
of/IN
beta2/NN
-microglobulin/NN
,/,
and/CC
a/DT
higher/JJR
disease/NN
activity/NN
score/RB
./.
====================
Also/RB
,/,
pSjS/NN
patients/NNS
who/WP
had/VBD
a/DT
history/JJ
of/IN
lymphoma/NN
showed/VBD
higher/JJR
levels/NNS
of/IN
Flt-3L/NN
./.
====================
Moreover/RB
,/,
the/DT
Flt-3L/NN
levels/NNS
were/VBD
increased/VBN
in/IN
the/DT
serum/NN
up/IN
to/TO
about/RB
8/CD
years/NNS
before/IN
the/DT
diagnosis/NN
of/IN
lymphoma/NN
./.
====================
This/DT
study/NN
has/VBZ
suggested/VBN
an/DT
ideal/JJ
cutoff/JJ
value/NN
of/IN
Flt-3L/NN
(/(
175/CD
pg/ml/NN
)/)
for/IN
an/DT
association/NN
with/IN
lymphoma/NN
in/IN
patients/NNS
with/IN
pSjS/JJ
(/(
44/CD
%/NN
for/IN
sensitivity/NN
,/,
97.5/CD
%/NN
for/IN
specificity/NN
,/,
and/CC
97/CD
%/NN
for/IN
negative/JJ
predictive/JJ
value/NN
)/)
./.
====================
Exosome/DT
====================
Exosomes/NNS
are/VBP
small/JJ
membrane-bound/JJ
macrovesicles/NNS
(/(
30–100/CD
nm/NN
in/IN
size/NN
)/)
secreted/VBN
from/IN
various/JJ
types/NNS
of/IN
cells/NNS
[/(
52/CD
]/)
./.
====================
They/PRP
resemble/JJ
flattened/JJ
spheres/NNS
under/IN
the/DT
electron/NN
microscope/NN
[/(
53/CD
,/,
54/CD
]/)
./.
====================
Exosomes/NNS
are/VBP
known/VBN
to/TO
have/VB
a/DT
number/NN
of/IN
biological/JJ
functions/NNS
,/,
such/JJ
as/IN
intracellular/JJ
communication/NN
,/,
signal/NN
transduction/NN
,/,
transport/VBP
of/IN
genetic/JJ
materials/NNS
,/,
and/CC
modulation/NN
of/IN
immune/JJ
responses/NNS
[/(
54/CD
]/)
./.
====================
They/PRP
can/MD
be/VB
found/VBN
in/IN
various/JJ
bodily/RB
fluids/NNS
such/JJ
as/IN
plasma/NN
,/,
serum/NN
,/,
breast/NN
milk/NN
,/,
saliva/NN
,/,
and/CC
urine/NN
[/(
55/CD
]/)
./.
====================
Recent/JJ
studies/NNS
have/VBP
reported/VBN
miRNAs/NNS
for/IN
SjS/NN
biomarkers/NNS
in/IN
these/DT
fluids/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
controversial/JJ
whether/IN
miRNAs/NNS
detected/VBN
in/IN
many/JJ
of/IN
those/DT
body/NN
fluids/NNS
are/VBP
circulating/VBG
freely/RB
or/CC
are/VBP
concentrated/VBN
in/IN
exosomes/NNS
[/(
56/CD
]/)
./.
====================
To/TO
compare/VB
miRNA/NN
expression/NN
in/IN
the/DT
exosome/JJ
pellet/NN
and/CC
the/DT
exosome-depleted/JJ
fraction/NN
of/IN
serum/NN
and/CC
saliva/NN
,/,
Gallo/JJ
et/FW
al/JJ
./.
====================
[/(
17/CD
]/)
measured/VBN
miRNA/NN
expression/NN
by/IN
qRT-PCR/NN
./.
====================
The/DT
study/NN
examined/VBD
miRNAs/NNS
previously/RB
reported/VBD
to/TO
be/VB
freely/RB
circulating/VBG
or/CC
miRNAs/NNS
known/VBN
to/TO
be/VB
exosome-specific/JJ
./.
====================
The/DT
concentration/NN
of/IN
miRNAs/NNS
was/VBD
consistently/RB
higher/JJR
in/IN
the/DT
exosome-pellet/NN
compared/VBN
to/TO
the/DT
exosome-depleted/JJ
supernatant/JJ
./.
====================
Selected/VBN
miRNAs/NNS
that/DT
are/VBP
known/VBN
to/TO
be/VB
detectable/JJ
in/IN
exosomes/NNS
were/VBD
undetectable/JJ
in/IN
whole/JJ
serum/NN
and/CC
the/DT
exosome-depleted/JJ
supernatant/JJ
./.
====================
Therefore/RB
,/,
the/DT
study/NN
concluded/VBD
that/IN
miRNAs/NNS
are/VBP
primarily/RB
present/JJ
in/IN
exosomes/NNS
./.
====================
However/RB
,/,
the/DT
authors/NNS
found/VBD
their/PRP$
data/NNS
inconsistent/VBP
with/IN
two/CD
other/JJ
previously/RB
published/VBN
studies/NNS
;/:
one/CD
indicating/VBG
that/IN
miRNAs/NNS
were/VBD
predominantly/RB
found/VBN
in/IN
exosome-free/JJ
cell/NN
culture/NN
media/NNS
[/(
57/CD
]/)
,/,
and/CC
another/DT
showing/VBG
that/IN
miRNAs/NNS
were/VBD
bound/VBN
to/TO
Argonaut-2/NN
protein/NN
in/IN
plasma/NN
and/CC
serum/NN
[/(
58/CD
]/)
./.
====================
The/DT
authors/NNS
speculated/VBD
that/DT
the/DT
discrepancy/NN
could/MD
be/VB
,/,
in/IN
part/NN
,/,
due/JJ
to/TO
minor/JJ
differences/NNS
in/IN
purifying/VBG
exosomes/VBZ
or/CC
differences/NNS
between/IN
plasma/NN
and/CC
serum/NN
./.
====================
The/DT
study/NN
emphasizes/VBZ
the/DT
utilization/NN
of/IN
exosomal/JJ
miRNA/NN
for/IN
early/JJ
biomarker/NN
studies/NNS
to/TO
reduce/VB
false-negative/JJ
results/NNS
when/WRB
detecting/VBG
low/JJ
abundance/NN
miRNAs/NNS
and/CC
the/DT
importance/NN
of/IN
optimized/VBN
exosome/JJ
purification/NN
process/NN
./.
====================
Since/IN
the/DT
initial/JJ
publications/NNS
in/IN
2011/CD
,/,
numerous/JJ
studies/NNS
have/VBP
discovered/VBN
unique/JJ
sets/NNS
of/IN
miRNAs/NNS
that/DT
may/MD
play/VB
a/DT
critical/JJ
role/NN
in/IN
SjS/NN
disease/NN
pathogenesis/NN
./.
====================
Some/DT
miRNAs/NNS
have/VBP
been/VBN
reported/VBN
as/IN
novel/JJ
biomarkers/NNS
for/IN
SjS/NN
while/IN
other/JJ
miRNAs/NNS
are/VBP
uniquely/RB
expressed/VBN
in/IN
certain/JJ
tissues/NNS
or/CC
in/IN
biological/JJ
samples/NNS
of/IN
SjS/NN
in/IN
comparison/NN
with/IN
controls/NNS
;/:
however/RB
,/,
the/DT
specificity/NN
and/CC
sensitivity/NN
of/IN
SjS-associated/JJ
miRNAs/NNS
along/IN
with/IN
their/PRP$
functional/JJ
implications/NNS
are/VBP
yet/RB
to/TO
be/VB
confirmed/VBN
by/IN
in-depth/DT
analyses/NNS
./.
====================
MiRNA/NN
studies/NNS
tend/VBP
to/TO
utilize/VB
a/DT
relatively/RB
small/JJ
sample/NN
size/NN
,/,
partly/RB
due/JJ
to/TO
cost-intensive/JJ
high-throughput/JJ
approaches/NNS
;/:
therefore/RB
,/,
results/VBZ
should/MD
be/VB
confirmed/VBN
in/IN
an/DT
independent/JJ
cohorts/NNS
of/IN
patients/NNS
,/,
ideally/RB
in/IN
collaboration/NN
with/IN
other/JJ
centers/NNS
or/CC
institutes/NNS
./.
====================
In/IN
addition/NN
,/,
as/IN
SjS/NN
is/VBZ
a/DT
clinically/RB
heterogeneous/JJ
disease/NN
,/,
selection/NN
of/IN
eligible/JJ
patients/NNS
for/IN
a/DT
study/NN
can/MD
be/VB
challenging/VBG
./.
====================
Furthermore/RB
,/,
different/JJ
assay/NN
systems/NNS
with/IN
different/JJ
stringency/NN
tend/NN
to/TO
yield/VB
inconsistent/JJ
data/NNS
among/IN
studies/NNS
as/IN
well/RB
./.
====================
Ever/RB
evolving/VBG
diagnostic/JJ
criteria/NNS
can/MD
certainly/RB
add/VBP
one/CD
more/RBR
layer/NN
of/IN
complexity/NN
when/WRB
it/PRP
comes/VBZ
to/TO
patient-oriented/JJ
studies/NNS
./.
====================
To/TO
minimize/VB
those/DT
challenges/NNS
and/CC
avoid/JJ
unnecessary/JJ
confusions/NNS
over/IN
the/DT
collected/JJ
data/NNS
,/,
it/PRP
would/MD
be/VB
desirable/JJ
to/TO
establish/VB
a/DT
consensus/NN
over/IN
diagnostic/JJ
criteria/NNS
and/CC
subject/JJ
eligibility/NN
among/IN
investigators/NNS
before/IN
initiating/VBG
a/DT
new/JJ
study/NN
./.
====================
Translation/NN
of/IN
current/JJ
discoveries/NNS
will/MD
allow/VB
the/DT
identification/NN
of/IN
biomarkers/NNS
and/CC
development/NN
of/IN
miRNA-based/JJ
therapeutics/NNS
in/IN
the/DT
near/JJ
future/JJ
./.
====================
miRNA/JJ
therapeutics/NNS
are/VBP
known/VBN
to/TO
provide/VB
specificity/NN
,/,
efficacy/NN
,/,
and/CC
markedly/RB
reduced/VBD
toxicity/NN
compared/VBN
to/TO
other/JJ
treatment/NN
modalities/VBZ
[/(
59–61/CD
]/)
./.
====================
A/DT
development/NN
of/IN
miRNA-targeted/JJ
molecular/JJ
therapy/NN
in/IN
autoimmune/JJ
diseases/NNS
,/,
especially/RB
for/IN
SjS/NN
,/,
would/MD
be/VB
an/DT
exciting/VBG
treatment/NN
option/NN
in/IN
the/DT
near/JJ
future/JJ
./.
====================
Further/RB
understanding/NN
of/IN
the/DT
regulatory/JJ
network/NN
of/IN
miRNA/JJ
expression/NN
will/MD
expedite/VB
the/DT
development/NN
of/IN
the/DT
miRNA-targeted/JJ
,/,
personalized/VBD
therapy/NN
./.
====================
With/IN
different/JJ
forms/NNS
of/IN
RNAs/NNS
such/JJ
as/IN
long/JJ
non-coding/JJ
RNAs/NNS
actively/RB
being/VBG
investigated/VBN
recent/JJ
years/NNS
,/,
discoveries/VBZ
of/IN
non-coding/JJ
RNA/NN
species/NNS
that/IN
have/VBP
been/VBN
reported/VBN
to/TO
date/NN
in/IN
the/DT
field/NN
of/IN
SjS/NN
may/MD
only/RB
be/VB
the/DT
tip/NN
of/IN
the/DT
iceberg/NN
./.
====================
miRNAs/NNS
involved/VBN
in/IN
Sjögren/NN
’/CD
s/NNS
syndrome/NN
====================
